A detailed history of Citigroup Inc transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 25,666 shares of STOK stock, worth $308,761. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,666
Previous 15,144 69.48%
Holding current value
$308,761
Previous $204,000 54.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$12.24 - $15.92 $128,789 - $167,510
10,522 Added 69.48%
25,666 $315,000
Q2 2024

Aug 12, 2024

BUY
$11.03 - $17.52 $106,748 - $169,558
9,678 Added 177.06%
15,144 $204,000
Q1 2024

May 10, 2024

BUY
$4.12 - $14.17 $6,155 - $21,169
1,494 Added 37.61%
5,466 $73,000
Q4 2023

Feb 09, 2024

BUY
$3.37 - $5.4 $11,363 - $18,208
3,372 Added 562.0%
3,972 $20,000
Q3 2023

Nov 09, 2023

SELL
$3.78 - $11.99 $33,521 - $106,327
-8,868 Reduced 93.66%
600 $2,000
Q2 2023

Aug 10, 2023

BUY
$7.93 - $13.82 $68,380 - $119,169
8,623 Added 1020.47%
9,468 $100,000
Q1 2023

May 11, 2023

SELL
$7.65 - $10.38 $1,507 - $2,044
-197 Reduced 18.91%
845 $7,000
Q4 2022

Feb 09, 2023

SELL
$7.07 - $15.69 $1,074 - $2,384
-152 Reduced 12.73%
1,042 $9,000
Q3 2022

Nov 10, 2022

SELL
$12.56 - $22.53 $18,011 - $32,308
-1,434 Reduced 54.57%
1,194 $15,000
Q2 2022

Aug 10, 2022

SELL
$10.36 - $23.93 $185,775 - $429,112
-17,932 Reduced 87.22%
2,628 $35,000
Q1 2022

May 12, 2022

SELL
$17.19 - $26.1 $588,482 - $893,507
-34,234 Reduced 62.48%
20,560 $433,000
Q4 2021

Feb 10, 2022

BUY
$18.11 - $30.72 $270,327 - $458,557
14,927 Added 37.44%
54,794 $1.32 Million
Q3 2021

Nov 10, 2021

BUY
$23.65 - $34.44 $942,854 - $1.37 Million
39,867 New
39,867 $1.01 Million

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $474M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.